Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples by Liechti, Thomas et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Development of a high-throughput bead based assay system to measure
HIV-1 specific immune signatures in clinical samples
Liechti, Thomas; Kadelka, Claus; Ebner, Hanna; Friedrich, Nikolas; Kouyos, Roger D; Gunthard,
Huldrych F; Trkola, Alexandra
Abstract: The monitoring and assessment of a broadly neutralizing antibody (bnAb) based HIV-1 vac-
cine require detailed measurements of HIV-1 binding antibody responses to support the detection of
correlates of protection. Here we describe the development of a flexible, high-throughput microsphere
based multiplex assay system that allows monitoring complex binding antibody signatures. Studying a
panel of 13 HIV-1 antigens in a parallel assessment of different IgG subclasses (IgG1, IgG2 and IgG3) we
demonstrate the potential of our strategy. The technical advances we describe include means to improve
antigen reactivity using directed neutravidin-biotin immobilization of antigens and biotin saturation to
reduce background. A particular emphasis of our study was to provide tools for the assessment of repro-
ducibility and stability of the assay system and strategies to control for variations allowing the application
in highthroughput assays, where reliability of single measurements needs to be guaranteed.
DOI: https://doi.org/10.1016/j.jim.2017.12.003
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-145408
Published Version
 
 
Originally published at:
Liechti, Thomas; Kadelka, Claus; Ebner, Hanna; Friedrich, Nikolas; Kouyos, Roger D; Gunthard,
Huldrych F; Trkola, Alexandra (2018). Development of a high-throughput bead based assay system
to measure HIV-1 specific immune signatures in clinical samples. Journal of Immunological Methods,
454:48-58.
DOI: https://doi.org/10.1016/j.jim.2017.12.003
Contents lists available at ScienceDirect
Journal of Immunological Methods
journal homepage: www.elsevier.com/locate/jim
Development of a high-throughput bead based assay system to measure
HIV-1 speciﬁc immune signatures in clinical samples
Thomas Liechtia,1,2, Claus Kadelkaa,b,2, Hanna Ebnera,2, Nikolas Friedricha, Roger D. Kouyosa,b,
Huldrych F. Güntharda,b, Alexandra Trkolaa,⁎
a Institute of Medical Virology, University of Zurich, Switzerland
bDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
A R T I C L E I N F O
Keywords:
HIV-1 binding antibody response
Microsphere based multiplex antigen binding
assay
High-throughput screen
A B S T R A C T
The monitoring and assessment of a broadly neutralizing antibody (bnAb) based HIV-1 vaccine require detailed
measurements of HIV-1 binding antibody responses to support the detection of correlates of protection. Here we
describe the development of a ﬂexible, high-throughput microsphere based multiplex assay system that allows mon-
itoring complex binding antibody signatures. Studying a panel of 13 HIV-1 antigens in a parallel assessment of diﬀerent
IgG subclasses (IgG1, IgG2 and IgG3) we demonstrate the potential of our strategy. The technical advances we describe
include means to improve antigen reactivity using directed neutravidin-biotin immobilization of antigens and biotin
saturation to reduce background. A particular emphasis of our study was to provide tools for the assessment of re-
producibility and stability of the assay system and strategies to control for variations allowing the application in high-
throughput assays, where reliability of single measurements needs to be guaranteed.
1. Introduction
Broadly neutralizing antibody (bnAb) responses are considered a
key element of protective vaccines against HIV-1 (Burton and
Hangartner, 2016). Evaluation of vaccine candidates in animal models
and in human trials not only requires measuring of the desired function,
a broad neutralization activity, but also a thorough assessment of a
broad range of binding antibody properties elicited by the vaccine to
conﬁrm correlates of protection. This was highlighted by the RV144
study (Chung et al., 2014; Haynes et al., 2012), where non-neutralizing
antibodies directed against the V2 region of the envelope protein were
linked with the modest protection observed in this trial. Besides the
observation that these V2 antibodies can induce ADCC, strong IgG3
responses were observed in RV144 highlighting a potential protective
eﬀect of Ab eﬀector functions (e.g. antibody dependent cellular cyto-
toxicity) in this trial (Chung et al., 2014). Several other studies reported
on the high variability of HIV-1 binding antibody response in terms of
IgG subclass distribution, elicitation of eﬀector functions and (Chung
et al., 2014) epitope recognition in natural infection and upon vacci-
nation (Chung et al., 2014; Chung et al., 2015; Brown et al., 2012).
These types of studies depend on sensitive and accurate binding
assays that allow assessment of many parameters in 100 s–1000 s of
samples. Customized multiplex immunoassays have been described to
detect binding antibody responses against HIV-1 infection (Brown et al.,
2012; Yates et al., 2011; Tomaras et al., 2008) and in the context of
HIV-1 vaccine studies (Haynes et al., 2012). Using this technology,
binding of IgG to the V1V2 region of the envelope protein was revealed
as a correlate of protection in the RV144 vaccine study (Haynes et al.,
2012). In addition, by delineating the contribution of individual im-
munoglobulin G isotypes Chung et al. revealed that two vaccine studies,
namely RV144 and VAX003, resulted in the elicitation of antibodies
consisting of diﬀerent isotypes (Chung et al., 2014). This is particularly
interesting, since both vaccine studies used the same recombinant
protein gp120 AIDSVAX B/E. However, the RV144 study used a canary
pox vector (ALVAC-HIV vCP1521) to prime the immune system and
recombinant gp120 AIDSVAX B/E boost while the study VAX003
primed with a single dose of recombinant gp120 AIDSVAX B/E, which
emphasizes that the selection of antigen and regimen can inﬂuence the
distribution of isotypes elicited during vaccination. These observations
highlight the importance of multiplex immunoassays to capture the
complexity of antibody responses against HIV-1 and other pathogens.
Here we report on the development of a microsphere bead-based
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multiplex immunoassay technology to measure binding responses
against multiple HIV-1 derived proteins and peptides of diﬀerent Ig
subtypes. The method we describe allows improved coupling to beads
over published protocols, includes a broader range HIV-1 derived pro-
teins and peptides and provides a full quality assessment that allows to
run large sample sets without the necessity to obtain repeat measure-
ments. The latter is a pre-requisite for true high-throughput screening
assays.
2. Methods
2.1. Clinical samples and ethics information
All analyzed plasma samples were derived from specimen stored in the
biobanks of the Swiss HIV Cohort study (SHCS) and the Zurich Primary HIV
Infection Study (ZPHI). The Swiss HIV Cohort Study (SHCS) is a pro-
spective, nationwide, longitudinal, non-interventional, observational,
clinic-based cohort with semi-annual visits and blood collections, enrolling
all HIV-infected adults living in Switzerland (Swiss et al., 2010). The SHCS
is registered under the Swiss National Science longitudinal platform: http://
www.snf.ch/en/funding/programmes/longitudinal-studies/Pages/default.
aspx#Currently%20supported%20longitudinal%20studies. Detailed in-
formation on the study is openly available on http://www.shcs.ch. The
Zurich Primary HIV Infection study (ZPHI) is an ongoing, observational,
non-randomized, single center cohort founded in 2002 that speciﬁcally
enrolls patients with documented acute or recent primary HIV-1 infection
(www.clinicaltrials.gov; ID NCT00537966) (Rieder et al., 2011).
The SHCS and the ZPHI have been approved by the ethics com-
mittee of the participating institutions (Kantonale Ethikkommission
Bern, Ethikkommission des Kantons St. Gallen, Comite departemental
d'ethique des specialites medicales et de medicine communataire et de
premier recours, Kantonale Ethikkommission Zürich, Repubblica e
Cantone Ticino - Comitato Ethico Cantonale, Commission cantonale
d'étique de la recherche sur l'être humain, Ethikkommission beider
Basel for the SHCS and Kantonale Ethikkommission Zürich for the
ZPHI) and written informed consent had been obtained from all parti-
cipants.
2.2. HIV-1 antigens and antibodies
We selected 13 HIV-1 antigens covering structural Gag proteins
(p17 and p24) and various Env antigens (gp120 JR-FL, BG505 gp140,
BG505 trimer, V3 and MPER peptides, CD4bs probes (RSC3, RSC3Δ) for
the development of the assays. Properties, sources and details to pro-
duction and puriﬁcation of HIV-1 antigens are listed in Supplementary
Table 1. We thank contributors to the NIH AIDS Reagent Program, D.
Burton (TSRI, USA), J.P. Moore (Cornell University, USA), R. Sanders
(AMC, Netherlands), P. D. Kwong (NIH-VRC, USA), M. Nussenzweig
(The Rockefeller University, USA), J. Robinson (UZH, Switzerland) for
providing proteins, peptides or expression plasmids for this study. All
peptides were chemically biotinylated as indicated in Supplementary
Table 1. With the exception of p24 and gp41ΔMPER all other proteins
were expressed with an avi-tag and enzymatically mono-biotinylated
(Avidity, LLC, Colorado, USA). Supplementary Table 2 contains in-
formation on all the monoclonal antibodies used in this study.
2.3. Detection of HIV-speciﬁc IgG isotypes using a customized multivariate
multiplex bead assay
To measure plasma IgG1, IgG2, IgG3 binding antibody reactivity to
the 13 selected Gag and Env HIV-1 antigens we established a bead-
based multiplexed immunoassay using the Luminex technology©.
Carboxylated MagPlex© beads (Luminex) were either covalently di-
rectly coupled with antigens or coupled with Neutravidin (Sigma
Aldrich) followed by loading with biotinylated antigens. MagPlex©
beads contain unique ratios of two ﬂuorescent dyes which allow the
distinction of up to 500 diﬀerent so-called bead regions. Choosing un-
ique bead regions for each antigen/analyte allowed to perform in-
dividual measurements in one simultaneous reaction. Coupling was
done using a coupling kit (BioRad) according to the manufacturer's
instructions. Brieﬂy, 12.5 Mio beads were sonicated and thoroughly
washed with the activation buﬀer provided by the coupling kit. The
carboxyl groups on the beads were activated in 100 μl activation buﬀer
containing sulfo-N-hydroxysulfosuccinimide (S-NHS, Thermo Fisher
Scientiﬁc) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro-
chloride (EDC, Thermo Fisher Scientiﬁc) at a concentration of 5 mg/ml.
After 20 min of activation at room temperature beads were thoroughly
washed with activation buﬀer and beads were coupled in 500 μl PBS
containing the respective proteins (50 μg of gp41ΔMPER, 62.5 μg p24)
for direct coupling or 62.5 μg neutravidin for 2 h at room temperature.
Beads were then washed thoroughly, blocked with PBS-BSA 1% for
30 min at room temperature and after extensive washing stored in PBS-
BSA 1% at a bead concentration of 20,000 beads/μl at 4 °C. Biotinylated
proteins were coated on neutravidin-coupled beads and subsequently
blocked with biotin. Proteins and biotin were diluted in PBS at a con-
centration of 320 nM (if not stated otherwise) and coating and blocking
were performed for 1 h at room temperature. Beads were extensively
washed with PBS-BSA 1% and stored at a concentration of
10,000 beads/μl at 4 °C and were used for up to 56 days.
Patient plasma was heat inactivated at 56 °C for 1 h before use the
binding assay. The diﬀerent bead regions carrying the diﬀerent antigens
were mixed at each experiment and incubated with patient plasma or
monoclonal Abs diluted in PBS-BSA 1% over night at 4 °C to allow plasma
IgG binding to antigen-coated beads. Beads were washed with PBS-BSA 1%
and split up equally into 3 diﬀerent reactions to allow for detection of IgG1,
IgG2 and IgG3 from the same plasma sample. IgG responses were detected
with phycoerythrin (PE)-labeled secondary antibodies speciﬁc to isotypes
IgG1 (Southern Biotech, Cat#9054-09, clone HP6001), IgG2 (Southern
Biotech Cat#9070-09, clone HP6002), IgG3 (Southern Biotech Cat#9210-
09, clone HP6050) or total anti-human IgG (Southern Biotech Cat#9040-
09, clone JDC-10) diluted in PBS-BSA 1% at a concentration of 1 μg/ml for
1 h at room temperature. After extensive washing with PBS/BSA 1% beads
were analyzed with the FlexMap 3D or LX200 instruments (Luminex). A
minimum of 50 beads per antigen and plasma were acquired to guarantee
accurate MFI values. Quality control and validation procedures for the
FlexMap 3D instrument were done on each day of experiment according to
manufacturer's instructions.
2.4. Detection and exclusion of measurements aﬀected by the Hook eﬀect
To assess the performance of the assay we probed plasma samples from
8 chronically HIV-1 infected individuals against the complete antigen panel.
Plasma samples were probed over a range of dilutions, in four completely
independent replicates on multiple days. For each plasma dilution curve
(where each data point is the geometric mean of the four replicate mea-
surements), we determined the dilution at which the maximal signal in-
tensity was measured (Supplementary Fig. 6). This is usually the lowest
(1:100) dilution. If this was not the case, all lower dilutions were identiﬁed
as aﬀected by the Hook eﬀect, which is a well-described phenomenon likely
caused by an overabundance of plasma antibodies (Hoofnagle and Wener,
2009). In Fig. 4 and Supplementary Fig. 7, where the focus is on the day
post bead coupling, we used a stringent approach and excluded, for each
antigen and each plasma, all measurements at a ﬁxed dilution where at least
the measurement on one of the ﬁve days was aﬀected by the Hook eﬀect.
This particular choice of exclusion ascertains that all investigated distribu-
tions of log binding titers are based on the same plasma samples and
measured at the same dilution, while minimizing the number of excluded
plasma samples.
As quality control all measurements were assessed for Hook eﬀects
and plasma samples aﬀected by it were excluded form further analysis.
No other means of quality control or sample exclusions were performed.
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2.5. Exponential curve ﬁtting
For each patient plasma, each dilution and each antigen, we used an
exponential decay model to quantify the observed decrease in signal in-
tensity over time post bead coupling (Fig. 4B). Let y be the measured MFI
and let x be the day post bead coupling. Fitting a linear regression model
log10y=m x+ b to the data and transformation of the slope m yields
= −%change in signal intensity per week 100(10 1)m7
2.6. Assay variability
To assess the performance of the assay we probed plasma samples from
8 chronically HIV-1 infected individuals against the complete antigen panel.
Plasma samples were probed over a range of dilutions, in four completely
independent replicates on multiple days. We measured the (intra-plasma)
assay variability as the coeﬃcient of variation of the log binding titers
across the four replicates (Fig. 5) and as the standard deviation of the log
binding titers across the four replicates (Fig. 6). In addition, we measured
the (inter-plasma) assay variability as the standard deviation of the average
log binding titers (over the four replicates) across the eight tested plasma
samples (Fig. 6). For all analyses (Figs. 5–6 and Table 1), measurements of
the intra- or inter-plasma assay variability that were aﬀected by the Hook
eﬀect were excluded (see Section 2.4).
2.7. Strategy to optimize the choice of dilution(s)
In high-throughput experiments, plasma samples can only be tested
at a few dilutions. The following strategy identiﬁes the optimal dilu-
tions for high-throughput experiments given that m≥ 1 dilutions can
be tested. In a pre-experiment, several randomly chosen plasma sam-
ples are tested against all antigens of interest and at various dilutions (if
possible many, covering a large range); using e.g. a 96-well plate, one
could measure 8 plasma samples at 12 dilutions. Let A be the set of
antigens, and let D be the set of tested dilutions. For each antigen a ∈ A
and each dilution d ∈ D, the inter-plasma diﬀerences (standard devia-
tions of the measurements) are computed, denoted by sda. To avoid
choosing dilutions that show high inter-patient diﬀerences due to the
Hook eﬀect, the number of aﬀected measurements is calculated for each
dilution and each antigen (see Methods), and sda = 0 is set manually for
antigens and dilutions, where> 10% (or some even lower threshold) of
the plasma samples are aﬀected. The best set Bm∗⊆ D of m dilutions is
the one that maximizes the sum of the inter-plasma diﬀerences,
∑=∗
⊆ ≤ ∈
∈
B sargmax max .m
B D B m a A d B
d
a
, | |
3. Results and discussion
3.1. Assay development – oriented, neutravidin-based bead immobilization
to improve signal to noise ratio
In the initial phase of our assay development we coupled HIV-1
derived proteins and peptides covalently to the carboxylated beads as
described previously (Brown et al., 2012) (Supplementary Fig. 1A and
Supplementary Table 1). We used the resurfaced core protein 3 (RSC3)
(Wu et al., 2010), a protein designed to be preferentially recognized by
CD4 binding site (CD4bs)-speciﬁc antibodies and the construct RSC3Δ
(Wu et al., 2010), which lacks a crucial site required for CD4bs Ab
binding, to assess the potentials of the assays. Direct coupling of RSC3
and RSC3Δ yielded the expected results both displaying good binding of
the glycan speciﬁc Ab 2G12 as described (Wu et al., 2010) and no cross-
reactivity with the V3-speciﬁc 1–79, MPER-speciﬁc 2F5 or polyclonal
human IgG from healthy donors (Fig. 1A). In addition RSC3 showed
speciﬁc binding of the CD4bs speciﬁc monoclonal antibodies b12 and
VRC01 whereas RSC3Δ did not. While speciﬁcity was therefore as
desired, the obtained signals were in general low and did not exceed a
median ﬂuorescence intensity (MFI) value of 100 with the Luminex
LX200 which has an upper MFI limit of 35,000.
Based on this we next took measures to improve the signal-to-noise
ratio. Covalent linkage of proteins to carboxylated proteins via primary
and secondary amines can result in random orientation of the protein
on the beads resulting in masking of the epitope of interest in a fraction
of the proteins (de Jager and Rijkers, 2006; Schwenk et al., 2007). As
this could be a problem for probes like RSC3, we developed a procedure
for covalent linking of neutravidin to beads and coating the neu-
travidin-coupled beads with site-directed biotinylated proteins (Sup-
plementary Fig. 1B). This guarantees that all proteins are displayed in
the same (known) orientation on the beads.
NA coupling resulted in dramatically increased signals of CD4bs
bnAb b12 and VRC01 binding to RSC3 (Fig. 1A). At the same time NA
coupling had no eﬀect on binding of the same bnAbs to RSC3Δ nor was
2G12 binding to both proteins altered. Identical binding of 2G12 irre-
spective of the antigen coupling highlights that NA-coupling did not
result in higher quantities of proteins on beads compared to direct-
coupling and hence NA-coupling must overcome a negative eﬀect on
epitope accessibility that exists in the case of direct coupling (Fig. 1A).
We next tested the diﬀerentially coupled antigens for their capacity to
detect CD4bs speciﬁc IgG (i.e. RSC3 reactive) in plasma of six individuals
with acute (n=3) and chronic (n=3) HIV-1 infection (Fig. 1B). In line
with the known delay in Ab development in HIV-1 infection, we detected no
Speciﬁc CD4bs Ab activity in the three acutely infected persons. In contrast
all three chronically infected cases showed reactivity with RSC3, which was
higher for NA-coupled versus the direct coupled beads (Fig. 1B). These
results strongly emphasize that coating of biotinylated proteins on neu-
travidin carrying beads results in highly improved signal-to-noise ratio
compared to the classical approach.
3.2. Assay development – reducing background noise
In a separate line of experiments we sought to ﬁnd means to reduce
background noise. Proteins and peptides contain charged moieties that may
enhance aggregation. Theoretically aggregated proteins could pose a problem
to the measurement, as they may unspeciﬁc ally bind to beads and also
potentially could be transferred between beads loaded with diﬀerent probes.
During the actual measurement where beads loaded with diﬀerent proteins/
peptides are present this could contribute to a noise signal. We thus in-
troduced a blocking step with free biotin that was applied immediately after
coupling the biotinylated probes to NA on the beads. This blocking step en-
sures occupation of free binding pockets of neutravidin and resulted in dra-
matically reduced background noise signals as shown for the reactivity to NA-
coupled signals with the background control composed of neutravidin-cou-
pled beads without coated biotinylated protein (Supplementary Fig. 2).
3.3. Assay development – assessing the advantage of NA-coupled antigens
for HIV-1 Ab analysis
To verify if biotinylated proteins provide a general advantage in signal
detection, we next assessed binding of several mAbs to BG505 trimer. For
this comparison BG505 trimer was either directly coupled to beads or N-
terminal biotinylated BG505 was coupled to NA coated beads. The BG505
trimer adopts a closed conformation and thus is known to bind bnAbs more
eﬃciently than non- or weak neutralizing antibodies (Sanders et al., 2013).
Indicators for a closed conformation are bnAbs like PG09 and PG16, which
preferentially bind quaternary structures compared to Env monomers. Our
comparison of the two coupling methods revealed that irrespective of the
coupling method weak- or non-neutralizing antibodies did not bind BG505
trimer (Fig. 1C). In contrast however, binding of bnAbs to the NA-coupled
trimer was greatly increased (Fig. 1C and D). Interestingly the increase in
PG09 and PG16 was proportionally higher (Fig. 1D) emphasizing that the
biotin/neutravidin approach provides a better preservation of the trimer
structure.
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The BG505 trimer contains the immunodominant HR1 and HR2 regions
of gp41 monoclonal antibodies against the gp41 failed to bind the trimer
due to its closed native-like structure (Sanders et al., 2013). To verify that
NA coupling does not lead to a distortion of the conformation in this area,
we tested the reactivity of gp41 mAbs with NA-immobilized N-terminally
biotinylated trimer. To this end we tested a panel of gp120- and gp41-
speciﬁc antibodies for the ability to bind to the BG505 trimer or the trimeric
gp41 lacking MPER (gp41ΔMPER). The BG505 trimer was only recognized
by gp120-directed but not gp41 antibodies. In line with published reactiv-
ities (Yasmeen et al., 2014), the bnAbs VRC01, PG09, PG16, PGT121 and
2G12 were the most eﬃcient in binding the trimer (Fig. 2A and B). While
the gp41-speciﬁc antibodies did not bind the BG505 trimer, they yielded
high signals using the gp41ΔMPER (Fig. 2A and B). To further verify this,
we tested binding of plasma from 25 chronically infected patients to BG505
trimer and gp41ΔMPER and probed if binding is aﬀected by competition
with soluble gp41ΔMPER (Supplementary Fig. 3). We observed a dose-de-
pendent decrease in plasma Ab binding to gp41ΔMPER but not the BG505
trimer conﬁrming that gp41-directed antibodies cannot bind to the native-
like BG505 trimer. Collectively these results highlight that neutravidin/
biotin coupling of BG505 trimer to beads does not alter the conformation of
the protein and preserves its intact native-like closed structure.
In a further step, to ensure that our assay provides the best possible signal-
to-noise ratio we titrated diﬀerent concentrations of biotinylated, monomeric
gp120 JR-FL on neutravidin-coupled beads to test whether the signal in-
tensity can be improved when the protein density on beads is increased
(Supplementary Fig. 4). Increasing concentrations of gp120 JR-FL during
coating did not result in relevant increases of signals and MFI at saturation
and EC50 titers remained largely identical (Supplementary Fig. 4B) sug-
gesting that at the concentration range used all accessible NA sites are oc-
cupied. We therefore set the concentration of proteins during NA-bead
coating at 320 nM. Similar results were obtained with gp41ΔMPER coupled
directly to the beads suggesting that also for direct coupling a wide range of
protein concentrations on the beads results in consistent ﬂuorescence in-
tensities (Supplementary Fig. 4C and D).
3.4. Assay development – probing large NA-coupled bead panels
In a next development step we probed a multiplex panel of 13 HIV-1
protein/peptide targets (Fig. 3). Eleven of the targets were immobilized via
the NA-strategy; the remaining two (p24 and gp41ΔMPER, which were not
available with N-terminal biotinylation) were directly, covalently coupled to
the beads. Since both p24 and gp41 are highly immunodominant and gen-
erally elicit high antibody titers in HIV-1 infection (Graham et al., 1992;
Gnann Jr. et al., 1987), potentially decreased signals due to covalent linkage
were not a concern. Using this panel of 13 HIV-1 probes we generated
binding titers against all antigens for a range of HIV-1 mAbs with known
epitope speciﬁcity and a polyclonoal HIV-1 IgG pool from infected patients
(HIVIG) (Fig. 3). The results show the expected binding pattern for mAbs
according to their known epitope speciﬁcity.
HIVIG bound as expected for HIV-1 plasma antibodies well to p17,
p24 and gp41ΔMPER, but had surprisingly weak reactivity with gp120
JR-FL and beyond this with no other gp120 probe suggesting that the
overall gp120 Ab content in this pool is low. Collectively, these data
verify that the Luminex based multiplex assay we developed is highly
speciﬁc and that no crosstalk between the targets occurs.
3.5. Assay development – increasing the dimensionality of the
measurements by parallel assessment of IgG subclasses
A speciﬁc goal in our assay development was to create an assay that
provides the possibility to not only increase the panel size if this becomes of
interest but also to add a further layers of information by assessing speciﬁc
properties of antibodies. A primary objective for us was to estimate the
contribution of IgG1, IgG2 and IgG3 to the HIV-1 binding antibody response.
To allow this we deﬁned a strategy where a given plasma sample is ﬁrst
incubated with the full panel of beads. After the IgG binding step, beads are
split into three diﬀerent reactions with speciﬁc secondary antibodies against
the diﬀerent IgG subclasses. In order to guarantee that the recorded signals
measured are indeed speciﬁc for the corresponding IgG isotype, we probed
the speciﬁcity of the secondary antibodies (Supplementary Figs. 1C and 5).
For this, commercially available standards for IgG1, IgG2 and IgG3 were
incubated with anti-IgG coupled Luminex beads and tested whether the
secondary antibodies cross-react with the diﬀerent IgG subclasses. Our results
indicate that the secondary antibodies are speciﬁc to the individual sub-
classes. We saw, however, some degree of cross reactivity of anti IgG-1 de-
tection Ab with the IgG3 standard, although only at very high concentrations
(Supplementary Fig. 5). Concentration of the IgG-1 detection Ab used routi-
nely in our assay were set to 1 μg/ml so that no cross-reactivity could inﬂict
our measurements.
3.6. Assessment of assay performance
Luminex binding assays have been used in several studies to mea-
sure antibody binding reactivities to HIV-1 antigens (Brown et al.,
2012; Tomaras et al., 2011; Moody et al., 2015) but the ability to detect
a broad range of epitopes and the diﬀerent isotypes contributing to the
signal was not yet assessed in detail.
To test the reproducibility, variability of our assay system we con-
ducted an in-depth multiplex binding analysis of plasma samples from 8
chronically HIV-1 infected individuals using the full panel of 13 HIV-1
antigen described above. The binding reactivities to the 13 HIV-1 an-
tigens were measured on 5 days (1, 6, 14, 34, 56 days post bead cou-
pling) at 6 diﬀerent plasma dilutions (3-fold dilutions from 1:100 to
1:24,300), and in 4 replicate assays. This large, multi-dimensional data
set allowed us to analyze the temporal assay stability, the assay varia-
bility, and the optimal dilution for each antigen.
For each tested HIV-1 antigen, each plasma sample and each day of
testing, we obtained dilution curves where each data point is the geo-
metric mean of four replicate measurements (Supplementary Fig. 6).
For some highly reactive antigens, we observed a clear Hook eﬀect
(Hoofnagle and Wener, 2009): the maximum signal intensity was not
reached at the lowest 1:100 dilution but at a higher dilution (Supple-
mentary Fig. 6), which is likely caused by an overabundance of plasma
antibodies. 23.9% of all measurements were aﬀected by this eﬀect (see
Methods) and we excluded them from all further analyses where they
might aﬀect the results.
3.6.1. Temporal assay stability
A speciﬁc interest of our analysis was to deﬁne temporal aﬀects. As
high-throughput screenings for which we designed the assay, com-
monly will require data acquisition over prolonged periods it is im-
portant to monitor and control for a potential decay of the antigen-bead
batches. Indeed we observed that the signal intensity decreased con-
tinuously over time and that this was already noticeable shortly after
coupling of the beads (Fig. 4A). This decrease was observed for most
antigens but more pronounced for antigens with weaker reactivity
(Supplementary Figs. 6 and 7). Although several explanations for this
observed loss of signal intensity may apply, likely reasons are constant
detachment of the protein coupled to the beads and protein decay. In
line with this, the decrease generally followed an exponential decay
pattern (Supplementary Fig. 8). This decay aﬀected all antigens irre-
spective of the mode of bead immobilizations but was less pronounced
for directly coupled antigens in our panel.
Fitting exponential regression models to curves as in Supplementary
Fig. 8 revealed widely varying decay rates across the 13 antigens
(Fig. 4B), with binding titers to antigens like V3 MN and MPER-2/4/10
decreasing by on average> 20% per week. This clearly demonstrates
that measurements obtained on diﬀerent days post bead coupling
cannot be compared without further adjustments. Based on our ex-
perience we strongly advocate that monitoring of temporal eﬀects need
to be generally incorporated when assessing reactivity over several days
to weeks by bead based assays.
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The signal intensity decreased very similarly for all 8 patients
(Supplementary Fig. 8). This is an important and positive ﬁnding as it
implies that the day post bead coupling – while it strongly aﬀects the.
absolute signal strength – does not inﬂuence the relative ranking of
the measured plasma samples. The Luminex assay can thus be con-
ducted at any day post bead coupling and plasma samples measured at
the same day can be compared directly in absolute terms. For larger
screens with measurements on multiple days, this also provides the
opportunity that the relative rankings of the plasma samples can be
compared. To minimize the risk of falsifying the data by the transfor-
mation to relative ranks, this requires two key conditions. First, the
order of the plasma samples must be randomized before the start of the
experiment. Second, the throughput of samples must be suﬃciently
high. We recently conducted a Luminex binding assay with 4281
plasma samples using the here described multiplex panel where we
measured 122–354 samples per day and recorded values in ordinal
ranks (Kadelka et al., in preparation), highlighting that processing
suﬃcient sample sizes are possible.
In low to medium throughput experiments, samples measured on the
same day can be compared for the absolute signal intensities. Ideally, stan-
dards should be included in each individual assay to account for the temporal
signal decay in these lower-throughput experiments. Here we report on a
diﬀerent control setting for high-throughput screens that does not require the
use of standards as it uses relative rank values. Standards (typically mono-
clonal antibodies in setups like ours) will not cover all speciﬁcities present in
polyclonal plasma (diﬀerent epitopes, diﬀerent aﬃnities, etc.). The relative
rank data of large plasma numbers run on the same assay day provide
therefore an ideal control to account for temporal signal decay that will cover
all potential speciﬁcities.
3.6.2. Assay variability
The assay variability, measured as the coeﬃcient of variation of the
binding titers across the four replicates, varied strongly (range:
0.0013–0.3425) but was overall small with a median of 0.0457 (Fig. 5A).
88.1% of all measurements showed< 10% variability and even
99.3%< 20% variability. Immunoassays with a CV of< 20% are con-
sidered accurate (Andreasson et al., 2015; Maecker, n.d.). Thus the Luminex
binding assay we describe here is generally reliable and reproducible.
We conducted further analyses to identify which factors are associated
with the assay variability in our assay system. Measurements with a higher
signal intensity resulted, on average, in more similar replicates (Fig. 5B).
Accordingly, the variability also diﬀered strongly across antigens with
binding to highly reactive antigens being measured more accurately
(Fig. 5C). The choice of plasma dilution also seemed to matter; we observed
the lowest average variability for a mid-range plasma dilution of 1:2700
(Fig. 5D). In addition, the time post bead coupling seemed to inﬂuence the
variability but the observed pattern was not monotonic (Fig. 5E). Im-
portantly, the actual sample measured exhibited no strong eﬀect on the
variability highlighting that assay speciﬁc factors but not handling or
sample composition have an inﬂuence (Fig. 5F).
3.7. Optimizing for high-throughput screens – single measurements at an
optimal plasma dilution
In the process of assay evaluations, we measured the binding re-
activities at six diﬀerent plasma dilutions and in four replicate assays.
This level of accuracy is not possible in large screens, where to be cost-
and time-eﬀective analyses ideally need to be restricted to a single
measurement of one plasma dilution. It was thus important to probe
what the optimal plasma dilution(s) are in our set-up that would allow
this. An intrinsic problem of multiplex assays is the highly varying re-
activity across diﬀerent antigens; there is hardly ever a single dilution
at which all investigated antigens are measured in the dynamic range.
Measurements in the dynamic range of the assay are characterized by
Table 1
Choice of optimal plasma dilution.
(A) The inter-patient diﬀerences, measured in standard deviations, are shown for each antigen and each dilution. Standard deviations where> 10% of the measurements are aﬀected
by the Hook eﬀect are written in gray and excluded from the choice of the optimal dilution. Bold font highlights the antigen-dependent optimal dilution, which maximizes the inter-
patient diﬀerences. (B) Example of the strategy designed to pick best dilutions for high-throughput screens. The sums considered for determining the next best dilution are computed from
the values in A, and at each step, the best dilution to be added is highlighted in shades of green. (A–B) Detailed dilution curves of the raw data are shown in Supplementary Fig. 6.
A Dilution
1:100 1:300 1:900 1:2700 1:8100 1:24300
Average inter-patient standard deviation 
HIV-1 
antigens
p17 0.098 0.052 0.026 0.021 0.033 0.068
p24 0.116 0.083 0.102 0.161 0.304 0.558
gp120 JR-FL 0.072 0.040 0.021 0.027 0.055 0.131
BG505 gp140 0.097 0.055 0.061 0.099 0.168 0.247
BG505 trimer 0.090 0.046 0.046 0.092 0.152 0.207
RSC3 0.101 0.056 0.070 0.162 0.357 0.529
RSC3Δ 0.344 0.417 0.421 0.353 0.214 0.063
V3 JR-FL 0.073 0.047 0.028 0.068 0.182 0.253
V3 MN 0.114 0.123 0.140 0.180 0.221 0.221
V3 BG505 0.178 0.142 0.137 0.203 0.278 0.265
MPER-2/4 0.218 0.259 0.316 0.368 0.375 0.302
MPER-2/4/10 0.198 0.212 0.222 0.230 0.231 0.184
gp41ΔMPER 0.098 0.052 0.029 0.031 0.033 0.051
B Dilution
1:100 1:300 1:900 1:2700 1:8100 1:24300
Find best dilution
sum of the average inter-patient standard 
deviations (excluding Hook-effect affected 
ones)
0.344 0.464 1.413 1.964 2.605 3.080
Find best two dilutions
sum of the gains in average inter-patient 
standard deviations (excluding Hook-
effect affected ones)
0.281 0.354 0.410 0.401 0.285 -
Find best three dilutions
sum of the gains in average inter-patient 
standard deviations (excluding Hook-
effect affected ones)
0 0 - 0.060 0.082 -
T. Liechti et al. Journal of Immunological Methods xxx (xxxx) xxx–xxx
5
comparably higher inter-patient diﬀerences, which we exploited to
determine the best plasma dilution for each antigen. We used the
average standard deviation between the measurements of the 8 patient
plasmas as a measure of the inter-patient diﬀerences, where the average
was taken across the four replicates and the ﬁve days of testing. Of the
probed dilutions, the dynamic range of highly reactive antigens like p24
or the BG505 trimer seemed best hit by a 1:24,300 dilution, while this
dilution was worst suited for measuring RSC3Δ binding as all mea-
surements were in the lower plateau of the assay (Table 1, Supple-
mentary Fig. 6). A comparison of the inter- and intra-patient variability
of the measurements revealed a signiﬁcantly larger variation among
plasma samples from diﬀerent donors than among replicates for each
antigen (Fig. 6), which supports the validity of using single measure-
ments in high-throughput experiments. In addition, results obtained
from large population-wide screens are generally robust to potential,
single outliers. In low-throughput screens, on the other hand, replicate
measurements are advisable.
Above results also show that a range of dilutions yields measurements in
the dynamic range of the assay (Table 1, Supplementary Fig. 6). Since high-
throughput experiments need to be time- and cost- eﬀective, only one, or at
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Fig. 1. Improving signal-to-noise ratio by developing a new Luminex assay based on biotinylated proteins and peptides and neutravidin-coupled beads.
(A) Comparison of antibody binding to RSC3 (CD4bs probe) and RSC3Δ (CD4bs deﬁcient probe) coupled covalently to Luminex beads (red bars) or via biotin to neutravidin (NA)-coupled
Luminex beads (blue bars) in a Luminex bead binding assay. CD4bs speciﬁc antibodies (VRC01 and b12) known to bind RSC3 but not RSC3Δ and the glycan speciﬁc nAb 2G12 known to
binds both constructs were used to compare signal-to-noise ratio in the two diﬀerent coupling setups. NA only signiﬁes beads that were not coupled with antigen to establish the
background. Puriﬁed human IgG from healthy donors, V3-speciﬁc mAb 1–79 and the MPER-speciﬁc bnAb 2F5 were used as negative controls. (B) Comparison of plasma antibody
reactivity of acute (n= 3) and chronically (n= 3) HIV-1 infected individuals with the direct and NA coupled beads described in A. (C) Comparison of reactivity of gp120-speciﬁc mAbs
with BG505 trimer coupled covalently to beads (left) or through biotin on NA-coupled beads (right) were tested. Reactivity of weakly neutralizing (top row) and broadly neutralizing Abs
(bottom row) are shown. (A–C) Median Fluorescence intensity (MFI) values obtained in a representative experiment on an LX200 reader are shown. (D) The diﬀerence in binding signal to
BG505 trimer and BG505 gp140 between NA-coupled and directly coupled beads shown in C) is depicted.
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most a few, dilutions can be tested. We therefore designed the following
strategy to optimize the choice of dilution(s) for a given number of testable
dilutions: In a pre-experiment, several randomly chosen plasma samples are
tested against all antigens of interest and at various dilutions (if possible
many, covering a large range); using e.g. a 96-well plate, one couldmeasure 8
plasma samples at 12 dilutions. Since the dynamic range of an assay is
characterized by large diﬀerences among the measured plasma samples, our
strategy allows us to choose those dilutions for use in a high-throughput
screening that yield the highest sum of inter-plasma diﬀerences across all
tested antigens (see Methods for details). If at all possible, this strategy en-
sures that there is at least one dilution for each antigen that yields mea-
surements in the dynamic range of the assay.
For our data, the strategy identiﬁed the 1:24,300 dilution as the best
dilution (Table 1B). When allowing two dilutions, it added the 1:900
dilution, which provides a large gain in inter-patient diﬀerences for
RSC3Δ, an antigen that is measured very poorly at the 1:24,300 dilu-
tion. The two identiﬁed dilutions plus the 1:8100 dilution were iden-
tiﬁed as the best set of three dilutions. The gain in total inter-patient
diﬀerences per added dilution dropped quickly indicating support for
the use of only a few dilutions in high-throughput experiments as the
high associated cost of additional dilutions may often outweigh the
beneﬁt of a small increase in signal accuracy.
4. Conclusion
With antibody-based HIV-1 vaccine development moving closer to
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Fig. 2. BG505 trimer maintains closed conformation after coupling via biotin on neutravidin-coupled beads.
(A) Binding reactivities of gp120-speciﬁc (top row) and gp41-speciﬁc (bottom row) antibodies against BG505 trimer (left column) and gp41ΔMPER (right column) were compared for
directly and biotin/NA-coupled beads in the Luminex binding assay. Median ﬂuorescence intensity (MFI) values obtained in a representative experiment on an LX200 reader are shown.
(B) 50% eﬀective concentration (EC50) values derived from data shown in (A) are depicted.
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large-scale HIV vaccine trials the necessity to have accurate assay sys-
tems that allow high-throughput and high-content analysis increases.
Several multiplex assays are described to analyze HIV-1 speciﬁc
binding antibody responses in HIV-1 infection or vaccine studies
(Brown et al., 2012; Yates et al., 2011; Tomaras et al., 2008). These
assays are extensively tested and include a variety of HIV-1 derived
proteins and peptides such as p24, gp120, and MPER peptides (Brown
et al., 2012; Tomaras et al., 2008). In addition, these assays were de-
veloped with the goal to elucidate the contribution of individual IgG
and IgA isotypes to antibody responses.
Here we describe the development of a sensitive multiplex bead-
based assay system that allows for simultaneous detection of antibodies
binding distinct target sites on the envelope trimer and other HIV-1
derived antigens. In addition to including new HIV-1 derived peptides
and proteins in the analysis of individual IgG isotypes (IgG1, IgG2 and
IgG3), we report a new system using site-directed biotinylated proteins
and peptides and neutravidin coupled beads. This new system guar-
antees the preservation of the antigenic structure compared to random
covalent coupling to carboxylated beads and improved the signal re-
solution and dynamic range. The assay system provides means to dif-
ferentiate HIV-1 binding antibody signatures in HIV-1 infected in-
dividuals or vaccinees. Using the same procedures as we applied here
(NA coupling of targets) other targets or host responses can be easily
approached. As we lay out here, a comprehensive knowledge of the
assay performance in terms of variability and stability is required to
allow application in high-throughput testing. Importantly, we show
that once the relevant factors are known, they can be controlled for,
enabling accurate high-throughput measurements.
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four replicate assays. For each antigen and each patient plasma, all measurements at a ﬁxed dilution where at least one of the measurements on the ﬁve days was aﬀected by the Hook
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